Therapeutic strategies targeting PKM2 aim to manipulate these regulatory mechanisms, either by stabilizing the active tetramer to force maximal glycolytic flux (PK activators), thereby starving the tumor of anabolic building blocks, or by inhibiting PKM2 activity to starve the tumor of energy (PK inhibitors) (Figure 6) (126). Here, PKM is linked to neoplasm.